Current understanding suggests that liver disease results in a state of rebalanced haemostasis due to alterations in both pro- and anti-haemostatic factors, including reduced levels of alpha-2 antiplasmin and plasminogen, as well as increased levels of tissue plasminogen activator (tPA) and PAI-1. The gene discussed is PLG; the disease is liver disorder.